MedPath

Tagged News

BioMed X and Servier Launch First European XSeed Labs to Advance AI-Driven Bispecific Antibody Design

AIDrug DiscoveryOncology
  • BioMed X and Servier have launched the first XSeed Labs in Europe at the Spartners incubator in Paris-Saclay, implementing a crowdsourcing model that embeds academic researchers within pharmaceutical R&D facilities.
  • The inaugural research project focuses on developing an AI-empowered platform for sterically guided design of bispecific antibodies, addressing key physical constraints that limit therapeutic effectiveness.
  • The initiative seeks to overcome steric hindrance, epitope accessibility, and spatial dynamics challenges that currently evade systematic design principles in bispecific antibody development.
  • Researchers worldwide are invited to submit interdisciplinary proposals combining antibody engineering, AI/machine learning, structural biology, and immuno-oncology expertise by August 31, 2025.

Cresset Acquires Molab.ai to Enhance AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Cresset, a leading provider of computational chemistry solutions, has acquired German AI company Molab.ai to advance digitization of drug discovery workflows.
  • The strategic acquisition combines Cresset's computational chemistry platform with Molab.ai's proven capability to build highly predictive ADME models for molecular research.
  • Molab.ai's AI-driven software has been successfully applied in real-world projects to improve molecular property prediction, lead optimization, and virtual screening processes.
  • The integration will offer researchers a unified platform for rapid and accurate prediction of biological activity and ADME properties, accelerating the path from molecule to medicine.

Cardio Diagnostics Partners with AGEPHA Pharma to Validate AI-Powered Precision Medicine Approach for Inflammation-Driven Coronary Heart Disease

Precision MedicineAI
  • Cardio Diagnostics has entered an agreement with AGEPHA Pharma to supply LODOCO® (low-dose colchicine) for a clinical study exploring precision-guided treatment of inflammation-driven coronary heart disease.
  • The study will utilize Cardio Diagnostics' PrecisionCHD™ AI-powered genetic-epigenetic blood test to identify patients with inflammation-driven CHD and monitor their response to anti-inflammatory therapy.
  • The PrecisionCHD™ test evaluates six DNA methylation markers that map to modifiable CHD drivers including inflammation, offering advantages over traditional imaging-based approaches for non-invasive monitoring.
  • This collaboration represents a precision medicine model where both diagnosis and treatment are guided by patients' unique molecular insights to maximize therapeutic outcomes.

Nobel Peace Prize Laureate James Orbinski Joins AI Drug Repurposing Startup Fifty 1 Labs

AI
  • Dr. James Orbinski, who received the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières, has joined Fifty 1 Labs as Senior Scientist to advance AI-driven drug repurposing initiatives.
  • The Nevada-based biotech company unveiled a strategic plan targeting the $320.6 billion functional medicine market through its AI platform that integrates clinical trial data and patent analytics.
  • Company leadership invested $350,000 of personal capital and deferred salaries until reaching a $50 million valuation, with plans for OTCQB uplisting by Q1 2026.
  • Fifty1 AI Labs LLC, the company's subsidiary, will receive $1 million in R&D funding to develop AI-driven drug repurposing technology aimed at delivering first discovery by May 2026.

BostonGene Partners with SWOG Cancer Research Network for AI-Driven Small Cell Lung Cancer Precision Medicine Trial

Precision MedicineAI
  • BostonGene and SWOG Cancer Research Network launched the PRISM study, a randomized Phase II trial evaluating biomarker-directed therapy for extensive stage small cell lung cancer patients.
  • The NCI-supported trial will enroll up to 900 patients and use BostonGene's AI-powered multiomics platform to identify molecular subtypes and assign personalized treatments.
  • Current standard treatment extends overall survival by only 2-3 months, with most patients experiencing disease progression despite combination chemotherapy and immunotherapy.
  • The study builds on previous SWOG S1929 trial findings that demonstrated promising improvements in progression-free survival using targeted approaches based on four distinct SCLC molecular subtypes.

Australian Scientists Develop PROTEUS Biological AI Platform to Accelerate Drug Discovery

AIDrug Discovery
  • Australian researchers have created PROTEUS, a groundbreaking "biological AI" platform that enables rapid evolution of molecules with new or enhanced functions directly inside mammalian cells.
  • The system represents a major breakthrough by allowing directed evolution within mammalian cells for the first time, previously limited to bacterial cells.
  • PROTEUS can reduce drug development processes from years to weeks by mimicking and accelerating natural selection.
  • The platform has been made open source to enable global adoption for developing advanced enzymes, molecular tools, therapeutics, and improved gene-editing medicines.

Predictive Oncology Secures $10M Equity Agreement to Advance AI-Driven Cancer Drug Discovery

AIDrug DiscoveryOncology
  • Predictive Oncology Inc. has entered into a $10 million standby equity purchase agreement with Yorkville Advisors to fund AI-driven drug discovery and repurposing initiatives.
  • The company's PEDAL AI platform demonstrates 92% accuracy in predicting tumor response to drug compounds, enabling more informed drug-tumor combination selection.
  • The flexible funding arrangement allows Predictive Oncology to control timing and amount of stock sales without minimum commitments or operational restrictions.
  • The partnership aims to accelerate drug discovery, biomarker discovery, and business development opportunities with leading biopharmaceutical companies.

Caris Life Sciences Validates AI-Powered Blood Test for Multi-Cancer Detection and Monitoring

AIPrecision Medicine
  • Caris Life Sciences published a landmark study in Scientific Reports validating the Caris Assure blood-based biopsy assay, which combines comprehensive molecular profiling of all 23,000+ genes across DNA and RNA in plasma.
  • The AI-powered platform achieved sensitivities of 83.1% to 95.7% across cancer stages I-IV at 99.6% specificity for multi-cancer early detection, trained on over 376,000 tissue profiles.
  • The assay demonstrated significant predictive power for recurrence monitoring with hazard ratios of 33.4 for minimal residual disease and 4.39 for therapeutic monitoring.
  • While currently available for therapy selection in advanced cancers, Caris is pursuing regulatory pathways to expand into early detection and disease monitoring applications.

Optibrium Secures Multi-Million Pound Financing to Accelerate AI-Powered Drug Discovery Platform

AIDrug Discovery
  • Optibrium, a leading developer of AI solutions for molecular design, secured a strategic multi-million-pound financing package from Shawbrook to accelerate drug discovery technology development.
  • The funding will enhance Optibrium's generative chemistry, collaborative design, and 3D molecular modeling capabilities while supporting global expansion of its computational chemistry platform.
  • Over 160 global pharmaceutical and biotech organizations currently use Optibrium's software suite for compound design and optimization, contributing to faster and more efficient drug discovery timelines.
  • The computer-aided drug discovery market is projected to grow from $4.21 billion in 2024 to $13.08 billion by 2034 at a 12% compound annual growth rate.

Veeda Lifesciences Partners with Mango Sciences to Deploy AI-Powered Platform for Enhanced Clinical Trial Diversity

AIOncology
  • Veeda Lifesciences has announced an investment in Boston-based Mango Sciences to leverage AI capabilities for enhancing clinical trial speed, efficiency, and quality across its global network.
  • The partnership will deploy Mango Sciences' AI-powered Querent platform to automate patient identification with precision and expand reach across Europe, particularly focusing on oncology drug development.
  • The collaboration aims to improve diversity in clinical trials through broader representation of non-Caucasian populations, meeting regulatory expectations and pharmaceutical company demands.
  • The integration of Large Language Models and Generative-AI into the Querent platform will drive operational efficiencies and improve real-world evidence for better patient-drug matching.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.